ArticlePloS one2015
Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- H7N9 influenza virus neutralizing antibodies that possess few somatic mutations.The Journal of clinical investigation · 2016Trial
- Neutralizing and protective monoclonal antibodies identify antigenic sites in influenza H7 hemagglutinin and select for amino acid substitutions rarely observed at the global level.Microbiology spectrum · 2026Article
- Direct airway delivery of a humanized anti-H7N9 neutralizing antibody broadly protects against divergent H7 influenza viruses in the mouse model.Journal of virology · 2025Article
- Pan-H7 influenza human antibody virus neutralization depends on avidity and steric hindrance.JCI insight · 2025Article
- Epitopes in the HA and NA of H5 and H7 avian influenza viruses that are important for antigenic drift.FEMS microbiology reviews · 2024Review
- Neutralizing and protective murine monoclonal antibodies to the hemagglutinin of influenza H5 clades 2.3.2.1 and 2.3.4.4.Influenza and other respiratory viruses · 2023Article
- Rapid determination of influenza vaccine potency by an SPR-based method using subtype or lineage-specific monoclonal antibodies.Frontiers in immunology · 2023Article
- Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic.Frontiers of medicine · 2021Review
- Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses.NPJ vaccines · 2021Article
- Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display.Scientific reports · 2021Article
- A Host-Restricted Self-Attenuated Influenza Virus Provides Broad Pan-Influenza A Protection in a Mouse Model.Frontiers in immunology · 2021Article
- Hemagglutination Inhibition (HAI) antibody landscapes after vaccination with H7Nx virus like particles.PloS one · 2021Article
- Review
- Development and optimized pairing of mouse monoclonal antibodies for detecting hemagglutinin in novel H7 subtype influenza viruses.Science China. Life sciences · 2020Article
- Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus.Emerging microbes & infections · 2020Article
- Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus.Viruses · 2019Article
- Molecular Evolution, Diversity, and Adaptation of Influenza A(H7N9) Viruses in China.Emerging infectious diseases · 2018Article
- Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.Emerging microbes & infections · 2018Article
- Potency determination of inactivated H7 influenza vaccines using monoclonal antibody-based ELISA and biolayer interferometry assays.Influenza and other respiratory viruses · 2018Article
- Immunocapture isotope dilution mass spectrometry in response to a pandemic influenza threat.Vaccine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying major antigenic and protective epitopes of the H7 hemagglutinin (HA) will be important for understanding the antibody response to vaccines developed against the novel influenza H7N9 viruses that emerged in China in 2013. To facilitate antigenic characterization of the H7N9 HA and to develop reagents for evaluation of H7N9 candidate vaccines, we generated a panel of murine monoclonal antibodies (mAbs) to the HA of A/Shanghai/2/2013 using mammalian cell-derived virus-like particles (VLP) containing the H7 HA. Neutralizing antibodies identified an HA epitope corresponding to antigenic site A on the structurally similar influenza H3 hemagglutinin. Importantly, the neutralizing antibodies protect against A/Shanghai/2/2013 challenge. This antigenic site is conserved among many H7 viruses, including strains of both Eurasian and North American lineage, and the isolated neutralizing antibodies are cross-reactive with older H7 vaccine strains. The results indicate that the identified antigenic site is a potentially important protective epitope and suggest the potential benefit of cross-reactive antibody responses to vaccination with H7 candidate vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.